Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 159

Similar articles for PubMed (Select 20185168)

1.

Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: a Gynecologic Oncology Group study.

Rose PG, Tian C, Bookman MA.

Gynecol Oncol. 2010 May;117(2):324-9. doi: 10.1016/j.ygyno.2010.01.040. Epub 2010 Feb 24.

PMID:
20185168
2.

The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.

Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P, Ryan A.

Health Technol Assess. 2008 May;12(15):iii-ix, xi-162. Review.

3.
4.

Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials.

Lara PN Jr, Redman MW, Kelly K, Edelman MJ, Williamson SK, Crowley JJ, Gandara DR; Southwest Oncology Group.

J Clin Oncol. 2008 Jan 20;26(3):463-7. doi: 10.1200/JCO.2007.13.0344.

5.

Chemotherapy in patients with recurrent or refractory epithelial ovarian cancer.

Satthapong D, Tangjitgamol S, Manusirivithaya S, Pataradool K.

J Med Assoc Thai. 2007 Mar;90(3):411-9.

PMID:
17427513
6.

Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.

Valentini V, Morganti AG, Gambacorta MA, Mohiuddin M, Doglietto GB, Coco C, De Paoli A, Rossi C, Di Russo A, Valvo F, Bolzicco G, Dalla Palma M; Study Group for Therapies of Rectal Malignancies (STORM).

Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1129-39. Epub 2006 Jan 18.

PMID:
16414206
7.

Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.

Holloway RW, Mehta RS, Finkler NJ, Li KT, McLaren CE, Parker RJ, Fruehauf JP.

Gynecol Oncol. 2002 Oct;87(1):8-16.

PMID:
12468336
8.

Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial.

Matei D, Schilder J, Sutton G, Perkins S, Breen T, Quon C, Sidor C.

Gynecol Oncol. 2009 Oct;115(1):90-6. doi: 10.1016/j.ygyno.2009.05.042. Epub 2009 Jul 4.

PMID:
19577796
9.

Pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients.

Gorumlu G, Kucukzeybek Y, Kemal-Gul M, Karaca B, Cosan-Terek M, Karabulut B, Sanli UA, Akman L, Ozsaran A, Dikmen Y, Uslu R.

J BUON. 2008 Jul-Sep;13(3):349-52.

PMID:
18979548
10.

A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study.

Sabbatini P, Sill MW, O'Malley D, Adler L, Secord AA; Gynecologic Oncology Group Study.

Gynecol Oncol. 2008 Dec;111(3):455-60. doi: 10.1016/j.ygyno.2008.07.049. Epub 2008 Sep 30.

PMID:
18829087
11.
12.

A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

Modesitt SC, Sill M, Hoffman JS, Bender DP; Gynecologic Oncology Group.

Gynecol Oncol. 2008 May;109(2):182-6. doi: 10.1016/j.ygyno.2008.01.009. Epub 2008 Mar 4.

PMID:
18295319
13.

CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.

Juretzka MM, Barakat RR, Chi DS, Iasonos A, Dupont J, Abu-Rustum NR, Poynor EA, Aghajanian C, Spriggs D, Hensley ML, Sabbatini P.

Gynecol Oncol. 2007 Jan;104(1):176-80. Epub 2006 Sep 25.

PMID:
16996584
14.

Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer.

McMeekin DS, Tillmanns T, Chaudry T, Gold M, Johnson G, Walker J, Mannel R.

Gynecol Oncol. 2004 Oct;95(1):157-64.

PMID:
15385126
15.

Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?

Radosavljevic D, Golubicic I, Gavrilovic D, Kezic I, Jelic S.

J BUON. 2009 Apr-Jun;14(2):203-9.

PMID:
19650167
16.

[Transarterial chemoperfusion of the pelvis--results in symptomatic locally recurrent tumors and lymph node metastases].

Vogl TJ, Zangos S, Eichler K, Balzer JO, Jacob U, Keilhauer R, Bauer RW.

Rofo. 2007 Nov;179(11):1174-80. Epub 2007 Sep 5. German.

PMID:
17805998
17.

Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study.

Schilder RJ, Sill MW, Lee RB, Shaw TJ, Senterman MK, Klein-Szanto AJ, Miner Z, Vanderhyden BC.

J Clin Oncol. 2008 Jul 10;26(20):3418-25. doi: 10.1200/JCO.2007.14.3420.

18.

A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients.

Kaern J, Baekelandt M, Tropé CG.

Eur J Gynaecol Oncol. 2002;23(5):383-9.

PMID:
12440808
19.

Phase II trial of CI-958 in recurrent platinum-refractory ovarian carcinoma. A Gynecologic Oncology Group Study.

Hoffman MA, Blessing JA, Morgan M.

Gynecol Oncol. 2000 Dec;79(3):463-5.

PMID:
11104620
20.

Medical therapy of advanced malignant epithelial tumours of the ovary.

Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A.

Forum (Genova). 2000 Oct-Dec;10(4):323-32. Review.

PMID:
11535983
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk